Primary malignant melanoma of the breast: A case report without relapse

Abstract

Objective: This study aimed to report the treatment and outcomes of a patient with primary malignant melanoma of the breast parenchyma using mastectomy as the main treatment.

Patient and methods: A 67-year-old female presented with a palpable lump approximately 2 cm in diameter in the lower inner quadrant of the left breast, and underwent ultrasound guided cutting needle biopsy. Cytological examination identified a malignant melanoma of the breast, and she received treatment with a modified radical mastectomy. Further assessment was carried out using a positron emission tomography/computed tomography, which negated the presence of a primary lesion in either adjacent or distant sites.

Results: After three years of follow-up with ultrasonography (USG) and mammography annually and a complete physical examination every six months in the clinic, the patient remained alive with no evidence of local or distant recurrence.

Conclusion: The surgical management of this case is appropriate according to the available literature up to the present. We recommend BRAF mutation testing and melanocytic marker testing for all patients to ensure the correct focus when selecting biomarker-based immunotherapy.

Keywords

melanoma / breast / malignancy / mastectomy

References

[1] Drueppel D, Schultheis B, Solass W, Ergonenc H, Tempfer CB. Primary malignant melanoma of the breast: case report and review of the literature. Anticancer Res. 2015;35(3):1709-1713.

[2] Kurul S, Taş F, Büyükbabani N, Mudun A, Baykal C, Çamlıca H. Different manifestations of malignant melanoma in the breast: a report of 12 cases and a review of the literature, Japanese. J Clin Oncol. 2005;35(4):202-206.

[3] Papachristou DN, Kinne DW, Rosen PP, Ashikari R, Fortner JG. Cutaneous melanoma of the breast. Surgery. 1979;85(3):322-328.

[4] Tan M, Howard A, Cyr AE. Malignant melanoma of the breast: a case report and review of the literature. Tumori Journal. 2013;99(1):e11-e13.

[5] Skarin A. Malignant skin lesion. Case 1: nevoid malignant melanoma of the breast presenting as a contralateral breast metastasis. Clin Oncol. 1999;17(12):3850-3852.

[6] Foley AL. A new technique for closing wounds after surgery for breast melanoma. Plast Reconstr Surg. 1995;95(2):418-419.

[7] Hussein MR. Extracutaneous malignant melanomas. Cancer Invest. 2008;26(5):516-534.

[8] Huang Q, Zhang XH, Guo LJ, He YJ. Surgery on primary melanoma of the breast. Transl Cancer Res. 2019;8(Suppl 5): S463-S468.

[9] Rassouli M, Voutsadakis IA. Primary noncutaneous malignant melanoma of the breast. Breast J. 2016;22(6):688-691.

[10] DeVita VT, Jr., Lawrence TS, Rosenberg SA. Devita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 12 ed. 2022.

[11] Mariana A. Origen del melanocito normal y maligno. Acta Bioquím Clín Latinoam. 2009;43(3):333-337.

[12] Koh J, Lee J, Jung SY, Kang HS, Yun T, Kwon Y. Primary malignant melanoma of the breast: a report of two cases. J Pathol Transl Med. 2019;53(2):119-124.

[13] He Y, Mou J, Luo D, Gao B, Wen Y. Primary malignant melanoma of the breast: a case report and review of the literature. Oncol Lett. 2014;8(1):238-240.

[14] Dang BQ, Miles B, Young P, He J, Nguyen QD. Rare primary malignant melanoma of the breast presenting as a solitary breast mass in a 43-year-old male. Cureus. 2023;15(11):e48114.

[15] Atkins MB, Lee SJ, Chmielowski B, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial- ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186-197.

[16] Bernardo MM, Mascarenhas MJ, Lopes DP. Primary malignant melanoma of the breast. Acta Med Port. 1980;2(1):39-43.

[17] Biswas A, Goyal S, Jain A, et al. Primary amelanotic melanoma of the breast: combating a rare cancer. Breast Cancer. 2014;21(2):236-240.

[18] Snashall E, Kiernan T, Harper-Machin A, Taghizadeh R. Primary melanoma of the breast parenchyma: an oncoplastic approach. Plast Reconstr Surg Glob Open. 2020;8(12):3276.

[19] Vanni I, Tanda ET, Spagnolo F, Andreotti V, Bruno W, Ghiorzo P. The current state of molecular testing in the BRAF-mutated melanoma landscape. Front Mol Biosci. 2020;7:113.

[20] Sorroche BP, Teixeira RJ, Pereira CAD, et al. PD-L1 tumor expression as a predictive biomarker of immune checkpoint inhibitors’ response and survival in advanced melanoma patients in Brazil. Diagnostics (Basel). 2023;13(6):1041.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.